Malcolm J. Moore
Impact in
- Oncology top 0.01%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 241
- Pancreatic and Hepatic Oncology Research 111
- Colorectal Cancer Treatments and Studies 86
- Cancer Treatment and Pharmacology 47
-
- Renal cell carcinoma treatment 34
- Lung Cancer Treatments and Mutations 32
- Gastric Cancer Management and Outcomes 26
- Co-authors
- Dongsheng Tu (33 shared papers)Mace L. Rothenberg (6 shared papers)Daniel D. Von Hoff (10 shared papers)Russell K. Portenoy (5 shared papers)Steven Gallinger (17 shared papers)M. Christine Cripps (4 shared papers)Anna Maria Storniolo (3 shared papers)Peter G. Tarassoff (3 shared papers)
- Journals
- Journal of Clinical Oncology (131 papers)Annals of Oncology (18 papers)Investigational New Drugs (14 papers)The Journal of Urology (12 papers)Clinical Cancer Research (11 papers)
- Partner nations
- CanadaUnited StatesAustralia
In The Last Decade
Malcolm J. Moore
350 papers receiving 36.1k citations
Malcolm J. Moore's Hit Papers
Peers
Comparison fields: 5 of 165
- Oncology 25.0k
- Cancer Research 7.3k
- Hepatology 2.9k
- Pulmonary and Respiratory Medicine 10.6k
- Pathology and Forensic Medicine 4.8k
Countries citing papers authored by Malcolm J. Moore
This map shows the geographic impact of Malcolm J. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm J. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm J. Moore more than expected).
Fields of papers citing papers by Malcolm J. Moore
This network shows the impact of papers produced by Malcolm J. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm J. Moore. The network helps show where Malcolm J. Moore may publish in the future.
Co-authors
The 25 scholars most cited alongside Malcolm J. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 358 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Hit paper breakdown → | 1997 | 4630 |
| 2 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 2909 |
| 3 | K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer Hit paper breakdown → | 2008 | 2764 |
| 4 | Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer Hit paper breakdown → | 2000 | 2368 |
| 5 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study Hit paper breakdown → | 2000 | 1678 |
| 6 | Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer Hit paper breakdown → | 2003 | 1605 |
| 7 | Cetuximab for the Treatment of Colorectal Cancer Hit paper breakdown → | 2007 | 1413 |
| 8 | Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer Hit paper breakdown → | 2005 | 1358 |
| 9 | Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial Hit paper breakdown → | 2014 | 1246 |
| 10 | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Hit paper breakdown → | 1996 | 1202 |
| 11 | Advanced pancreatic carcinoma: current treatment and future challenges Hit paper breakdown → | 2010 | 641 |
| 12 | Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer Hit paper breakdown → | 2009 | 504 |
| 13 | 1996 | 455 | |
| 14 | 2008 | 406 | |
| 15 | DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy Hit paper breakdown → | 2011 | 402 |
| 16 | 2012 | 354 | |
| 17 | 2007 | 354 | |
| 18 | 2014 | 311 | |
| 19 | 2015 | 268 | |
| 20 | 2005 | 256 |
About Malcolm J. Moore
Malcolm J. Moore is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Molecular Biology, having authored 358 papers that have together received 37.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (111 papers), Colorectal Cancer Treatments and Studies (86 papers), Cancer Genomics and Diagnostics (65 papers), Cancer Treatment and Pharmacology (47 papers), Renal cell carcinoma treatment (34 papers), Lung Cancer Treatments and Mutations (32 papers), Testicular diseases and treatments (29 papers) and Gastric Cancer Management and Outcomes (26 papers). The work is most often cited by research in Oncology (25.0k citations), Cancer Research (7.3k citations), Hepatology (2.9k citations), Pulmonary and Respiratory Medicine (10.6k citations) and Pathology and Forensic Medicine (4.8k citations). Malcolm J. Moore has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include Dongsheng Tu, Mace L. Rothenberg, Daniel D. Von Hoff, Russell K. Portenoy, Steven Gallinger, M. Christine Cripps, Anna Maria Storniolo, Peter G. Tarassoff, John Sahl Andersen and Derek J. Jonker. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs, The Journal of Urology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.